{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:12:23Z","timestamp":1790381543919,"version":"4.1.0"},"reference-count":20,"publisher":"European Respiratory Society (ERS)","issue":"1","funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2017,11,20]]},"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>We evaluated the efficacy and safety of ciprofloxacin dry powder for inhalation (DPI) in patients with non-cystic fibrosis bronchiectasis, two or more exacerbations in the previous year and pre-defined bacteria in sputum.<\/jats:p>\n                  <jats:p>In this phase III, double-blind, placebo-controlled trial, patients were randomised 2:1 to twice-daily ciprofloxacin DPI 32.5\u2005mg or placebo in two treatment regimens consisting of on\/off treatment cycles of 14 or 28\u2005days for 48\u2005weeks. The primary end-points were time to first exacerbation and frequency of exacerbations.<\/jats:p>\n                  <jats:p>\n                    A total of 416 patients were randomised to the 14-day on\/off regimen (ciprofloxacin DPI (n=137) and placebo (n=68)) or the 28-day on\/off regimen (ciprofloxacin DPI (n=141) and placebo (n=70)). Ciprofloxacin DPI 14\u2005days on\/off significantly prolonged time to first exacerbation\n                    <jats:italic>versus<\/jats:italic>\n                    pooled placebo (median time &gt;336\n                    <jats:italic>versus<\/jats:italic>\n                    186\u2005days; hazard ratio 0.53, 97.5% CI 0.36\u20130.80; p=0.0005) and reduced the frequency of exacerbations compared with matching placebo by 39% (mean number of exacerbations 0.6\n                    <jats:italic>versus<\/jats:italic>\n                    1.0; incidence rate ratio 0.61, 97.5% CI 0.40\u20130.91; p=0.0061). Outcomes for ciprofloxacin DPI 28\u2005days on\/off were not statistically significantly different from placebo. The safety profile of ciprofloxacin DPI was favourable.\n                  <\/jats:p>\n                  <jats:p>Ciprofloxacin DPI was well tolerated and has the potential to be an effective treatment option in non-cystic fibrosis bronchiectasis.<\/jats:p>","DOI":"10.1183\/13993003.02052-2017","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T20:10:16Z","timestamp":1516911016000},"page":"1702052","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":169,"title":["RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis"],"prefix":"10.1183","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8566-0344","authenticated-orcid":false,"given":"Anthony","family":"De Soyza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Aksamit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiemo-Joerg","family":"Bandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Criollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Stuart","family":"Elborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Operschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Polverino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2018,1,25]]},"reference":[{"key":"2024101909260625000_51.1.1702052.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201203-0487OC"},{"key":"2024101909260625000_51.1.1702052.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201309-1575OC"},{"key":"2024101909260625000_51.1.1702052.3","doi-asserted-by":"publisher","DOI":"10.1157\/13128330"},{"key":"2024101909260625000_51.1.1702052.4","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5694\/j.1326-5377.2010.tb03949.x","article-title":"Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand","volume":"193","author":"Chang","year":"2010","journal-title":"Med J Aust"},{"key":"2024101909260625000_51.1.1702052.5","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.118778"},{"key":"2024101909260625000_51.1.1702052.6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4155\/tde.14.3","article-title":"The PulmoSphere\u2122 platform for pulmonary drug delivery","volume":"5","author":"Weers","year":"2014","journal-title":"Ther Deliv"},{"key":"2024101909260625000_51.1.1702052.7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/jamp.2015.1282","article-title":"Ciprofloxacin dry powder for inhalation in patients with noncystic fibrosis bronchiectasis or chronic obstructive pulmonary disease, and in healthy volunteers","volume":"30","author":"Stass","year":"2017","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2024101909260625000_51.1.1702052.8","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00071312"},{"key":"2024101909260625000_51.1.1702052.9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cct.2017.05.007","article-title":"The RESPIRE trials: two phase III, randomised, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis","volume":"58","author":"Aksamit","year":"2017","journal-title":"Contemp Clin Trials"},{"issue":"Suppl. 2","key":"2024101909260625000_51.1.1702052.10","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0954-6111(11)70022-1","article-title":"Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?","volume":"105:","author":"Lo","year":"2011","journal-title":"Respir Med"},{"key":"2024101909260625000_51.1.1702052.11","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70165-1"},{"key":"2024101909260625000_51.1.1702052.12","unstructured":"Haworth CS , Wanner A , Froehlich J , et al. Inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection: results from two parallel phase III trials (ORBIT-3 and -4)). Multidiscip Respir Med 2018; in press."},{"key":"2024101909260625000_51.1.1702052.13","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.2.9607083"},{"key":"2024101909260625000_51.1.1702052.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.08.015"},{"key":"2024101909260625000_51.1.1702052.15","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2013.1056"},{"key":"2024101909260625000_51.1.1702052.16","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.20859"},{"key":"2024101909260625000_51.1.1702052.17","doi-asserted-by":"publisher","DOI":"10.1177\/1479972316643698"},{"key":"2024101909260625000_51.1.1702052.18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00018414"},{"key":"2024101909260625000_51.1.1702052.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00051-2017"},{"key":"2024101909260625000_51.1.1702052.20","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00026313"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02052-2017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:49:45Z","timestamp":1740361785000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02052-2017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,25]]},"published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1183\/13993003.02052-2017"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02052-2017","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732571639.793557655","asserted-by":"object"}]},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}